Latest Current Report
Filed: 2026-03-25
Key Insights
- Terns Pharmaceuticals has entered into a definitive agreement to be acquired by Merck for $53 per share, representing a significant premium for shareholders.
- The merger will be completed through a tender offer followed by a short-form merger, allowing for a timely and efficient acquisition process.
- Terns' outstanding equity awards, including stock options and RSUs, will be cancelled and converted into cash payments at the merger consideration price.